dailynewsnblog
T2D and obesity are interrelated metabolic conditions, with the liver playing a central role in disease progression.5,6 Survodutide, an investigational glucagon/ GLP-1 receptor (GCGR) dual agonist, is designed to target multiple underlying metabolic drivers by improving glycemic control, reducing appetite, and supporting reductions in liver fat.7,8,9 Notably, while glucagon is traditionally associated with raising blood glucose, survodutide’s dual mechanism may help improve insulin sensitivity and glucose management through its effects on liver fat reduction.7,10 This novel approach challenges conventional understanding of glucagon biology, suggesting that the specific balance of GCGR and GLP-1R agonism may help preserve glycemic control. Survodutide has not been approved for use, and its efficacy and safety have not been established.
